Journal of Jilin University(Medicine Edition) ›› 2019, Vol. 45 ›› Issue (04): 965-970.doi: 10.13481/j.1671-587x.20190440
• Review • Previous Articles
Research progress in PD-1/PD-L1 immune checkpoint inhibitors in treatment of non-smallcell lung cancer
-
Received:2018-09-21Published:2019-08-02
CLC Number:
- R734.2
Cite this article
share this article
| [1] ISHIDA Y, AGATA Y, SHIBAHARA K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11):3887-3895. [2] HE J, HU Y, HU M, et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J]. Sci Rep, 2015, 5:13110. [3] MEYERS D E, BRYAN P M, BANERJI S, et al. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer[J]. Curr Oncol, 2018, 25(4):324-334. [4] CEERAZ S, NOWAK E C, NOELLE R J. B7 family checkpoint regulators in immune regulation and disease[J]. Trends Immunol, 2013, 34(11):556-563. [5] FIFE B, BLUESTONE J. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J]. Immunol Rev, 2008, 224:166-182. [6] MAMALIS A, GARCHA M, JAGDEO J. Targeting the PD-1 pathway:a promising future for the treatment of melanoma[J]. Arch Dermatol Res, 2014, 306(6):511-519. [7] LIANG S C, LATCHMAN Y E, BUHLMANN J E, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses[J]. Eur J Immunol, 2003, 33(10):2706-2716. [8] LI XL, SHAO CS, SHI YF, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy[J]. J Hematol Oncol, 2018, 11(1):31. [9] THOMPSON R H, GILLETT M D, CHEVILLE J C, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma[J]. Cancer, 2005, 104(10):2084-2091. [10] TAUBE J M, ANDERS R A, YOUNG G D, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J]. Sci Translk Med, 2012, 4(127):127ra37. [11] DONG H, ZHU G, TAMADA K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12):1365-1369. [12] HIRANO F, KANEKO K, TAMURA H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity[J]. Cancer Res, 2005, 65(3):1089-1096. [13] DONG H, STROME S E, SALOMAO D R, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8):793-800. [14] TOPALIAN S L, TAUBE J M, ANDERS R A, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16(5):275-287. [15] CARBOGNIN L, PILOTTO S, MILELLA M, et al. Differential Activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1(PD-L1):sensitivity analysis of trials in melanoma, lung and genitourinary cancers[J]. PLoS One, 2015, 10(6):e0130142. [16] MA W J, GILLIGAN B M, YUAN J D, et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy[J]. J Hematol Oncol, 2016, 9(1):47-67. [17] RECK M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer[J]. Immunotherapy, 2018, 10(2):93-105. [18] LI J, JIE H B, LEI Y, et al. PD-1/SHP-2 inhibit Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment[J]. Cancer Res, 2015, 75(3):508-518. [19] SZNOL M, CHEN L. Antagonist antibodies to PD-1 and B7-H1(PD-L1) in the treatment of advanced human cancer:response[J]. Clin Cancer Res, 2013, 19(19):5542. [20] JUNEJA V R, MCGUIRE K A, MANGUSO R T, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity[J]. J Exp Med, 2017, 214(4):895-904. [21] TOPALIAN SL, HODI FS, BRAHMER JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-2454. [22] GETTINGER S N, HORN L, GANDHI L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 33(18):2004-2012. [23] GETTINGER S, HORN L, JACKMAN D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer:results from the CA209-003 study[J]. J Clin Oncol, 2018, 36(17):1675-1684. [24] RIZVI N A, MAZIÈRES J, PLANCHARD D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial[J]. Lancet Oncol, 2015, 16(3):257-265. [25] HORN L, SPIGEL D R, VOKES E E, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer:Two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35):3924-3933. [26] FONT E F, GETTINGER S N, BURGIO M A, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057):3-year update and outcomes in patients with liver metastases[J]. Ann Oncol, 2018, 29(4):959-965. [27] WU Y, LU S, CHENG Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC):results of the phase 3 CheckMate 078 study[C]. Chicago:AACR Annual Meeting, 2018. [28] CARBONE D P, RECK M, PAZARES L, et al. First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer[J]. N Engl J Med, 2017, 39(25):2415-2426. [29] HELLMANN M D, CIULEANU T E, PLUZANSKI A,et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104. [30] PAI-SCHERF L, BLUMENTHAL G M, LI H S, et al. FDA approval summary:pembrolizumab for treatment of metastatic non-small cell lung cancer:first-line therapy and beyond[J]. Oncologist, 2017, 22(11):1392-1399. [31] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550. [32] HUI R, GARON E B, GOLDMAN J W, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer:a phase 1 trial[J]. Ann Oncol, 2017, 28(4):874-881. [33] BORGHAEI H, LANGER C J, GADGEEL S, et al.24-Month overall survival from KEYNOTE-021 cohort G:pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small-cell lung cancer[J]. J Thorac Oncol, 2019.14(1):124-129. [34] GANDHI L, RODRÍGUEZ-ABREUD,GADGEELS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092. [35] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051. [36] HERBST R S, SORIA J C, KOWANETZ M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528):563-567. [37] FEHRENBACHER L, SPIRA A, BALLINGER M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846. [38] RITTMEYER A, BARLESI F, WATERKAMP D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066):255-265. [39] SOCINSKI M A, JOTTE R M, CAPPUZZO F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301. [40] JOTTE R M, CAPPUZZO F,VYNNYCHENKO L, et al. IMpower131:Primary PFS and safety analysis of a randomized phase Ⅲ study of atezolizumab+carboplatin+paclitaxel or nab-paclitaxel vs carboplatin+nab-paclitacel as 1L therpay in advanced squamous NSCLC[J]. J Clin Oncol, 2018, 36(Suppl 18):LBA 9000. [41] JIANG L Y, SU X Y, ZHANG T W, et al. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)[J]. Oncotarget, 2017, 8(16):26845-26857. [42] HIRSCH F R, MCELHINNY A, STANFORTH D, et al. PD-L1 immunohistochemistry assays for lung cancer:results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2):208-222. [43] MCLAUGHLIN J, HAN G, SCHALPER K A, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer[J]. JAMA Oncol, 2016, 2(1):46-54. [44] HAUSE R J, PRITCHARD C C, SHENDURE J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nat Med, 2016, 22(11):1342-1350. [45] RIZVI N A, HELLMANN M D, SNYDER A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124-128. |
| [1] | WANG Zhijing, SU Rongjian, DU Xiaoyuan. Effects of GRP78 on sensibility of gemcitabine on patients with NSCLC [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 595-600. |
| [2] | WANG Shangning, WANG Sisi, TIAN Shuyan, LI Jialin, LIU Wei. Early changes of peripheral blood lymphocyte subsets in patients with lung adenocarcinoma after single-port thoracoscopic lobectomy and their clinical significances [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 606-613. |
| [3] | LI Lijing, ZANG Yaru, YU Wenhui, LIANG Junwei, TONG Yanjun. Therapeutic effect of chemotherapy combined with sodium cantharidinate vitamin B6 injection in patientswith non-small cell lung cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1286-1290. |
| [4] | SUN Hongshuai, ZHU Hua, GAO Haiyan, WAN Guangcai, YU Xiuyan. Value of combined detection of tumor markers SCC-Ag, CEA, CYFRA21-1 and D-dimer in early diagnosis of non-small cell lung cancer [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1020-1024. |
| [5] | . Research progress in relationships between polymorphisms of DNA damage repair pathway gene and sensitivity and prognosis of non-small cell lung cancer treated with platinum drugs [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 869-874. |
| [6] | QUAN Xiaoyue, LIU Bailong, LIU Min, DONG Lihua. Treatment of lung squamous cell carcinoma with apatinib in patient who couldn't tolerate chemotherapy: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 624-627. |
| [7] | . Research progress in thoracic radiotherapy in limited-disease small cell lung cancer [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 190-194. |
| [8] | LIU Xiangliang, JI Wei, LI Li, ZHAO Yinghua, JIA Lin, WANG Zhiqiang, CHEN Xiao, LI Wei. Lung adenocarcinoma treated by Erlotinib HCL Tablets and chemotherapy combined with bevacizumab after drug resistance:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1019-1024. |
| [9] | LIU Danqing, YE Shufeng, TONG Weifang, TENG Bo, WANG Sanchun, FENG Qingjie. Renal clear cell carcinoma transferred to nasal cavity and sinuses:A case reportand literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 829-831. |
| [10] | . Progress research on effect of long non-coding RNA in occurrence and development of lung cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 450-453. |
| [11] | LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125. |
| [12] | XI Yanli, XU Na, LI Shu, WANG Di, WANG Shuran, NIU Fenglan. Inhibitory effect of gallic acid on proliferation of human non-small cell lung cancer A549 cells [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1092-1098. |
| [13] | . Progress research on mechanism of FGFR signaling pathway in pathogenesis of IPF and non-small cell lung cancer [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1254-1258. |
| [14] | YUN Fen, JIA Yongfeng, HAN Zhao, SUN Qinnuan, LI Xiuxia, YU Huiling. Expression of HIF-2αin non-small cell lung cancer tissue and its relationships with MVD,Ki67,and GST-π [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 954-957. |
| [15] | LIU Huanxin, ZHANG Guoxiang, GUO Linlang, TAN Songshan. Expression of miR-139-5p in small cell lung cancer tissue and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 942-948. |
|
||
